N-cadherin switching occurs in high Gleason grade prostate cancer
- PMID: 16173043
- DOI: 10.1002/pros.20334
N-cadherin switching occurs in high Gleason grade prostate cancer
Abstract
Background: The inappropriate expression of non-epithelial N-(neural) cadherin by epithelial cells, called cadherin switching, has been suggested to play a role in prostate cancer (PC) progression. We explored the role of N-cadherin as a biomarker in PC by correlating the expression with clinical parameters.
Methods: Two pathologists blinded to patients' history independently reviewed and scored the intensity and extent of staining of N-cadherin expression in 44 randomly selected radical prostatectomy specimens. The expression was correlated with total Gleason grade, individual Gleason patterns, tumor stage, and preoperative serum prostate specific antigen (PSA) levels and P-values < 0.05 were considered statistically significant.
Results: Of the 44 PC specimens, 14 (32%), 23 (52%), 7 (16%) consisted of Gleason grade 5-6, 7, and 8-10, respectively and 20/44 (45%) demonstrated N-cadherin expression. N-cadherin was expressed in 1/14 (7%) of Gleason 5-6 compared to 15/23 (65%) of Gleason grade 7, and 4/7 (57%) of Gleason grade 8-10, demonstrating a significant correlation between N-cadherin switching and higher Gleason grade (P = 0.001). While only about a third of primary or secondary Gleason pattern 3 demonstrated N-cadherin expression, a majority of Gleason patterns of > or = 4 expressed N-cadherin (P > 0.05), further suggesting that N-cadherin switching occurs with higher Gleason pattern. However, N-cadherin expression did not significantly correlate with preoperative serum PSA levels or tumor stage in our study cohort.
Conclusions: We have demonstrated for the first time that N-cadherin switching occurs in higher grade PC and correlates significantly with increasing Gleason patterns. N-cadherin may be as a useful biomarker of aggressive PC.
Copyright 2005 Wiley-Liss, Inc.
Similar articles
-
Aberrant expression of E-cadherin and beta-catenin in human prostate cancer.Urol Oncol. 2005 Nov-Dec;23(6):402-6. doi: 10.1016/j.urolonc.2005.03.024. Urol Oncol. 2005. PMID: 16301117
-
Metallothionein expression in prostatic carcinoma: correlation with Gleason grade, pathologic stage, DNA content and serum level of prostate-specific antigen.Clin Invest Med. 1997 Dec;20(6):371-80. Clin Invest Med. 1997. PMID: 9413634
-
Cadherin switching in human prostate cancer progression.Cancer Res. 2000 Jul 1;60(13):3650-4. Cancer Res. 2000. PMID: 10910081
-
Cadherin switching and bladder cancer.J Urol. 2010 Aug;184(2):423-31. doi: 10.1016/j.juro.2010.04.016. Epub 2010 Jun 17. J Urol. 2010. PMID: 20620393 Review.
-
Adhesion molecules expression as a potential marker of prostate cancer aggressivity. A TMA study of radical prostatectomy specimens.Arch Ital Urol Androl. 2006 Dec;78(4):130-4. Arch Ital Urol Androl. 2006. PMID: 17269615 Review.
Cited by
-
Soluble Neural-cadherin as a novel biomarker for malignant bone and soft tissue tumors.BMC Cancer. 2013 Jun 26;13:309. doi: 10.1186/1471-2407-13-309. BMC Cancer. 2013. PMID: 23799912 Free PMC article.
-
Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis.Proc Natl Acad Sci U S A. 2010 Feb 9;107(6):2485-90. doi: 10.1073/pnas.0908133107. Epub 2010 Jan 13. Proc Natl Acad Sci U S A. 2010. PMID: 20080667 Free PMC article.
-
Cell line modeling to study biomarker panel in prostate cancer.Prostate. 2016 Feb 15;76(3):245-58. doi: 10.1002/pros.23116. Epub 2015 Nov 2. Prostate. 2016. PMID: 26764245 Free PMC article.
-
The role of SRC family kinases in prostate cancer.Transl Oncogenomics. 2007 Oct 14;2:67-77. Print 2007. Transl Oncogenomics. 2007. PMID: 23641146 Free PMC article. No abstract available.
-
Androgen regulation of epithelial-mesenchymal transition in prostate tumorigenesis.Expert Rev Endocrinol Metab. 2011 May;6(3):469-482. doi: 10.1586/eem.11.32. Expert Rev Endocrinol Metab. 2011. PMID: 23667383 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous